 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
1 News |  |
| 12» |
- | Lu 177 zalsenertant tetraxetan (177Lu-IPN01087) / AstraZeneca
Preclinical, Journal: Enhanced Retention of NTSR1-Targeted Radionuclide Therapeutics via Covalent Inhibitors in Pancreatic, Colorectal, and Prostate Cancer Models. (Pubmed Central) - Mar 18, 2025
Incorporating the covalent inhibitor in [177Lu]Lu-NA-ET1 resulted in an improved retention and radiation dose delivery profile compared to [177Lu]Lu-3BP-227. Examination of the therapeutic potential of [177Lu]Lu-NA-ET1 and further exploration of the chemical biology of this approach is underway.
- || actinium-225 zalsenertant tetraxetan (225Ac-FPI-2059) / 3B Pharma, AstraZeneca
Enrollment closed: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours (clinicaltrials.gov) - Jan 28, 2025
P1, N=42, Active, not recruiting, Sponsor: Fusion Pharmaceuticals Inc.
Examination of the therapeutic potential of [177Lu]Lu-NA-ET1 and further exploration of the chemical biology of this approach is underway. Recruiting --> Active, not recruiting
- | AAA614 / 3B Pharma, Novartis
Journal: 177Lu-FAP-2286 Therapy in a Case of Squamous Lung Cancer. (Pubmed Central) - Dec 3, 2024
Radiological remission was observed on follow-up FAP imaging 7 months later with squamous cell carcinoma antigen decreased to normal level. No other abnormality monitored by routine laboratory examination was noted.
- | AAA614 / 3B Pharma, Novartis
Journal, Metastases: Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. (Pubmed Central) - Nov 26, 2024
[177Lu]Lu-FAPI-2286 PTRT, utilized for diverse cancer types, exhibited favorable tolerability in sarcoma patients, with minimal side effects, long-lasting retention of the radiopeptide within the tumor, and promising therapeutic effects. Preliminary findings of this prospective study need to be confirmed through further clinical trials.
- | 177Lu-OncoFAP-23 / Philogen
Preclinical, Journal: Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors. (Pubmed Central) - Oct 3, 2024
177Lu-OncoFAP and 177Lu-FAP-2286 were included in the biodistribution study as controls. OncoFAP-23 presents enhanced tumor uptake and tumor retention and low accumulation in healthy organs, findings that correspond to a strongly improved in
- AAA614 / 3B Pharma, Novartis
Comprehensive Preclinical Study and Administration Protocol for 177Lu-FAP-2286: Validation, Tumor Uptake, and Dosimetry Investigations (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_1530;
The validation of production and quality control processes for 177Lu-FAP-2286, along with the comprehensive preclinical studies and dosimetry investigations, demonstrate the potential for effective clinical translation. The use of lysine and arginine for kidney blockage, in combination with furosemide, shows promise in minimizing background activity in normal organs.
- AAA614 / 3B Pharma, Novartis
Development of Multivalent OncoFAP Derivatives for the Tumor-Targeted Delivery of Theranostic Radionuclides (Hall X1-X4) - Sep 27, 2024 - Abstract #EANM2024EANM_680;
We are launching a Phase I clinical trial to define the 177Lu-TriOncoFAP maximum tolerated dose, evaluating its safety profile, and collecting preliminary signs of efficacy. The compound will be given as single agent or in combination with L19-IL2 in patients with multiple types of FAP-positive tumors.
- AAA614 / 3B Pharma, Novartis
Initial experience with 177Lu-FAP-2286 peptide targeted radionuclide therapy in advanced solid tumors (Hall Y1-Y3) - Sep 27, 2024 - Abstract #EANM2024EANM_542;
177Lu-FAP-2286 PTRT seems to be a viable therapeutic option for FAP-positive tumors. However, due to variability in objective response, use in combination with single-agent chemo or immunotherapeutic agent is to be explored for better results.
- || Lu 177 zalsenertant tetraxetan (177Lu-IPN01087) / AstraZeneca
PK/PD data, Journal: Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. (Pubmed Central) - Sep 2, 2024
Through the side-by-side comparison, [64Cu]Cu-4b was identified as the lead agent for further evaluation based on its high and sustained tumor uptake and moderate liver uptake. It can not only be used to efficiently detect NTSR1 expression in lung cancer (for diagnosis, patient screening, and treatment monitoring), but also has the great potential to treat NTSR-positive lesions once chelating to the beta emitter 67Cu.
- |||| AAA614 / 3B Pharma, Novartis
Enrollment open: LuMIERE: A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (clinicaltrials.gov) - Aug 14, 2024
P1/2, N=222, Recruiting, Sponsor: Novartis Pharmaceuticals
It can not only be used to efficiently detect NTSR1 expression in lung cancer (for diagnosis, patient screening, and treatment monitoring), but also has the great potential to treat NTSR-positive lesions once chelating to the beta emitter 67Cu. Active, not recruiting --> Recruiting
- | AAA614 / 3B Pharma, Novartis
Journal, Metastases: 177Lu-FAP-2286 Therapy in a Patient With Metastatic Rhabdoid Meningioma. (Pubmed Central) - Aug 5, 2024
Herein, we reported a patient of rhabdoid meningioma with multiple liver, pancreas, and bone metastases, who received 177Lu-FAP-2286 therapy. After 1 treatment cycle, 68Ga-FAP-2286 PET/CT revealed partial remission of the lesions.
- || ITM-91 / 3B Pharma, ITM Isotopen Technologien Munchen
Trial completion date, Trial primary completion date, Metastases: GaLuCi: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 17, 2024
P1/2, N=170, Recruiting, Sponsor: Debiopharm International SA
After 1 treatment cycle, 68Ga-FAP-2286 PET/CT revealed partial remission of the lesions. Trial completion date: Jan 2027 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Jun 2027
- | AAA614 / 3B Pharma, Novartis
Journal, FDG PET, Metastases: Comparison of 68Ga-FAP-2286 and 18F-FDG PET/CT in the diagnosis of advanced lung cancer. (Pubmed Central) - Jul 16, 2024
However, the detection sensitivity for primary tumors using both modalities was comparable [100% (13/13) for both]. Compared to 18F-FDG PET/CT, 68Ga-FAP-2286 PET/CT demonstrated better lesion detection capabilities for lung cancer, particularly in lymph nodes and bone metastases, providing compelling imaging evidence for the efficacy of 177Lu-FAP-2286 treatment.
- Lu 177 zalsenertant tetraxetan (177Lu-IPN01087) / AstraZeneca
Elucidation of the Impact of Linker Modifications on the Biological Efficacy of Antagonistic NTSR1-Targeted Radionuclide Therapeutics for Colorectal Cancer (Exhibit Hall D - Science Pavilion (Convention Center); Screen 3; In-Person Only) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1581;
Substitution of aminoalkoxy-containing linkers resulted in prominent increases in renal uptake and retention. Further investigation into the impact of linker modifications in NTSR1- and other receptor-targeted antagonistic TRTs can improve the biological efficacy of agents.
- NTSR1 targeted radiopharmaceutical therapeutic - Full / Life Technologies Limited
Development of 177Lu-FL-091 for the treatment of NTSR1-positive cancers (717AB (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1231;
FL-091 displayed enhanced binding affinity to NTST1 and antagonist activity compared to 3BP-227. In addition, 177Lu-FL-091 demonstrated improved in vivo biodistribution profile vs.
- AAA614 / 3B Pharma, Novartis
Development of Multivalent OncoFAP Derivatives for the Tumor-Targeted Delivery of Theranostic Radionuclides (717AB (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1225;
We have recently completed GMP central labeling set-up. Philogen is launching a Phase I clinical trial to define the 177Lu-TriOncoFAP maximum tolerated dose, evaluating its safety profile, and collecting preliminary signs of efficacy.
- | Debio 0228 / Debiopharm, 3B Pharma
Preclinical, Journal: Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX. (Pubmed Central) - May 1, 2024
[177Lu]Lu-DPI-4452 demonstrated strong tumor growth inhibition in 2 xenograft mouse models. Thus, the 2 agents potentially provide a theranostic approach for selecting and treating patients with CAIX-expressing tumors such as ccRCC, CRC, and pancreatic ductal adenocarcinoma.
- | hemophilia therapy / 3B Pharma, Takeda
Journal: Riding the wave of change: Providing solid ground to support nursing with patient transitions to novel haemophilia therapies. (Pubmed Central) - Apr 22, 2024
Examples of these models in practice could give guidance and examples to reflect on for haemophilia nurses needing to make changes in their practice settings. These models of change, alongside existing haemophilia nurse competencies and tools such as the shared decision-making tool from the World Federation of Hemophilia, can assist the nurse to be a capable change agent to usher in these new innovations.
- | AAA614 / 3B Pharma, Novartis
Journal, Metastases: Metastatic Lung Adenocarcinoma Received Combined 177Lu-FAP-2286 Radiation Therapy and Targeted Therapy. (Pubmed Central) - Apr 10, 2024
After 1 treatment cycle, improvement of symptoms and radiological remission was observed. Moreover, the patient did not report any adverse effects.
- | AAA614 / 3B Pharma, Novartis
Journal, Metastases: 177Lu-FAP-2286 Therapy in a Metastatic Bone Malignant Solitary Fibrous Tumor. (Pubmed Central) - Apr 8, 2024
After 1 treatment cycle, 68Ga-FAP-2286 PET/CT revealed remission of the lesions. Moreover, the patient did not report any adverse effects.
- ||| AAA614 / 3B Pharma, Novartis
Enrollment closed, Trial completion date, Trial primary completion date: LuMIERE: A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (clinicaltrials.gov) - Feb 6, 2024
P1/2, N=222, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Moreover, the patient did not report any adverse effects. Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jul 2024 --> Jun 2026
- Debio 0228 / Debiopharm, 3B Pharma
First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma. (Level 1, West Hall; Poster Bd # E19) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_717;
P1/2
Very high SUVs and tumor-to-background ratios suggest potential for use in both diagnostics and patient selection for therapy. The tumor retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy.
- Lu 177 zalsenertant tetraxetan (177Lu-IPN01087) / AstraZeneca
Phase classification: Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. (clinicaltrials.gov) - Dec 12, 2023
P1, N=14, Terminated, Sponsor: Ipsen
The tumor retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy. Phase classification: P1/2 --> P1
- | 177Lu-FAP-2286 / 3B Pharma, Novartis
Journal, Metastases: 177Lu-FAP-2286 Therapy in a Case of Recurrent Bladder Cancer With Multiple Metastatic Lesions. (Pubmed Central) - Sep 13, 2023
Encouragingly, radiological remission and alleviation of his symptom were noted. In addition, the patient did not have any adverse effects.
- ||| AAA614 / 3B Pharma, Novartis
Enrollment change: LuMIERE: A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2023
P1/2, N=300, Recruiting, Sponsor: Clovis Oncology, Inc.
In addition, the patient did not have any adverse effects. N=170 --> 300
- Debio 0228 / Debiopharm, 3B Pharma
First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors. (On Demand | Hall A; Poster Bd # 354b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1859;
P1/2
N=170 --> 300 Radiolabeling DPI-4452 with gallium-68 ([68Ga]Ga-DPI-4452) or lutetium-177 ([177Lu]Lu-DPI-4452) is an innovative theranostic approach for identifying and treating patients (pts) with CA IX-expressing tumors...Eur J Nucl Med Mol Imaging 2022;49(Suppl 1):S1
- actinium-225 zalsenertant tetraxetan (225Ac-FPI-2059) / Fusion Pharma, 3B Pharma
NTSR1-targeted alpha therapeutic [Ac-225]-FPI-2059 induces growth inhibition in a preclinical colorectal tumor model (Section 19; Poster Board #12) - Mar 14, 2023 - Abstract #AACR2023AACR_7275;
Radiolabeling DPI-4452 with gallium-68 ([68Ga]Ga-DPI-4452) or lutetium-177 ([177Lu]Lu-DPI-4452) is an innovative theranostic approach for identifying and treating patients (pts) with CA IX-expressing tumors...Eur J Nucl Med Mol Imaging 2022;49(Suppl 1):S1 These results demonstrate that targeted delivery of [225Ac]-FPI-2059 to NTSR1 expressing tumors results in significant growth inhibition and enhanced survival, thereby providing promising preclinical evidence to support the clinical development of [225Ac]-FPI-2059.
- 177Lu-FAP-2286 / Clovis, 3B Pharma
Fibroblast activation protein (FAP)-targeted radiotherapy increases tumor CD8+ T cell infiltration and enhances response to PD-1 immune checkpoint blockade (Section 19; Poster Board #26) - Mar 14, 2023 - Abstract #AACR2023AACR_5058;
FAP-targeted radiopharmaceutical enhances PD-1-antibody-mediated TGI by increasing recruitment of tumor-infiltrating CD8+ T cells, which is enhanced and maintained in the presence of anti-PD-1. These findings provide a rationale for clinical studies of combined 177Lu-FAP-2286 radiotherapy and immune checkpoint blockade in FAP-positive tumors.
- ||| ITM-91 / 3B Pharma, ITM Isotopen Technologien Munchen
Enrollment open, Metastases: GaLuCi: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 15, 2023
P1/2, N=147, Recruiting, Sponsor: Debiopharm International SA
These findings provide a rationale for clinical studies of combined 177Lu-FAP-2286 radiotherapy and immune checkpoint blockade in FAP-positive tumors. Not yet recruiting --> Recruiting
- || actinium-225 zalsenertant tetraxetan (225Ac-FPI-2059) / 3B Pharma, AstraZeneca
Trial initiation date: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours (clinicaltrials.gov) - Feb 14, 2023
P1, N=42, Recruiting, Sponsor: Fusion Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Initiation date: Nov 2022 --> Feb 2023
- |||| ITM-91 / 3B Pharma, ITM Isotopen Technologien Munchen
New P1/2 trial, Metastases: GaLuCi: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 31, 2023
P1/2, N=147, Not yet recruiting, Sponsor: Debiopharm International SA
- || actinium-225 zalsenertant tetraxetan (225Ac-FPI-2059) / 3B Pharma, AstraZeneca
Enrollment open: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours (clinicaltrials.gov) - Dec 2, 2022
P1, N=42, Recruiting, Sponsor: Fusion Pharmaceuticals Inc.
Initiation date: Nov 2022 --> Feb 2023 Not yet recruiting --> Recruiting
- || actinium-225 zalsenertant tetraxetan (225Ac-FPI-2059) / 3B Pharma, AstraZeneca
New P1 trial: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours (clinicaltrials.gov) - Nov 4, 2022
P1, N=42, Not yet recruiting, Sponsor: Fusion Pharmaceuticals Inc.
- |||| 177Lu-FAP-2286 / Clovis, 3B Pharma
Clinical: Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial. @thomashopemd @UCSFCancer #oncology https://t.co/ae0d0alKir (Twitter) - Oct 24, 2022
- ||||| 177Lu-FAP-2286 / Clovis, 3B Pharma
Clinical: Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial. @thomashopemd @UCSFCancer #oncology https://t.co/U4STHU4UJ2 (Twitter) - Oct 22, 2022
- |||| 177Lu-FAP-2286 / Clovis, 3B Pharma
177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors @thomashopemd @UCSF @officialEANM #EANM #EANM22 #crcsm #hncsm #btsm #scmsm https://t.co/vcrENfOCLu (Twitter) - Oct 18, 2022
- | IPN1087 / Fusion Pharma
Journal: Examination of Charge Modifications of an Endolysosomal Trapping Inhibitor in an Antagonistic NTSR1-Targeted Construct for Colon Cancer. (Pubmed Central) - Jul 23, 2022
These four Lu-labeled, ET-enhanced, NTSR1-targeted agents (Lu-NA-ET1-4), along with the structurally analogous Lu-3BP-227, currently in clinical trials, underwent a battery of in vitro assays using HT-29 xenograft colon cancer cells to examine their NTSR1 binding, internalization and efflux, inhibition, and adduct formation properties...This study demonstrates that the ETs can be successfully incorporated into antagonistic NTSR1-targeted constructs without compromising their adduct formation capabilities. Based on these results, further exploration of the endolysosomal trapping approach is warranted in NTSR1- and other receptor-targeted antagonistic constructs.
- |||| 177Lu-FAP-2286 / Clovis, 3B Pharma
P1 data: We'll see how it plays out. The #LuMIERE trial is currently in Phase 1 studying 177Lu-FAP-2286, and should give us some insight into the future of FAP-targeted RLTs (NCT04939610). Hopefully we can deliver on the promise! (Twitter) - Jun 13, 2022
P1/2
- || 177Lu-FAP-2286 / Clovis, 3B Pharma
P1 data, Journal: Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using Lu-FAP-2286: First-in-Human Results. (Pubmed Central) - Apr 20, 2022
Lu-FAP-2286 PTRT, applied in a broad spectrum of cancers, was relatively well-tolerated with acceptable side effects and demonstrated long retention of the radiopeptide. Prospective clinical studies are warranted.
- ||| 177Lu-FAP-2286 / Clovis, 3B Pharma
$CLVS Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 https://t.co/sNQkvlfOZh (Twitter) - Mar 16, 2022
- 177Lu-FAP-2286 / Clovis, 3B Pharma
LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors (Section 35) - Mar 9, 2022 - Abstract #AACR2022AACR_5898;
P1/2
Secondary objectives include the assessment of radiation dosimetry, pharmacokinetics, and preliminary efficacy of 177Lu-FAP-2286 and the evaluation of safety and tumor uptake of 68Ga-FAP-2286. Phase 2 will evaluate the efficacy, safety, and dosimetry of 177Lu-FAP-2286 in patients with select FAP-expressing solid tumors.
- 177Lu-FAP-2286 / Clovis, 3B Pharma
Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46 (Section 25) - Mar 9, 2022 - Abstract #AACR2022AACR_5433;
P1/2
In preclinical studies, the radiotherapeutic 177Lu-FAP-2286 showed longer tumor retention, resulting in greater tumor inhibition than 177Lu-FAPI-46. The phase 1/2 LuMIERE clinical trial (NCT04939610) will evaluate FAP-2286 as a therapeutic (177Lu-FAP-2286) and imaging (68Ga-FAP-2286) agent in multiple indications.
- | Hemlibra (emicizumab-kxwh) / Roche, hemophilia therapy / 3B Pharma, Takeda
Journal: Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. (Pubmed Central) - Nov 12, 2021
The phase 1/2 LuMIERE clinical trial (NCT04939610) will evaluate FAP-2286 as a therapeutic (177Lu-FAP-2286) and imaging (68Ga-FAP-2286) agent in multiple indications. This consensus protocol will facilitate future evaluation of ITI outcomes in the evolving landscape of haemophilia therapeutics and ITI strategies.
- ||| FPI-2059 / Fusion Pharma
Preclinical: #NTSR1 Targeted #AlphaTherapeutic [#225Ac] #FPI2059 Induces Regression in Preclinical #Colorectal #XenograftModel https://t.co/aAVXN5A4ib (Twitter) - Oct 22, 2021
- FAP-2286 / Clovis, 3B Pharma
[VIRTUAL] Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286 () - Sep 30, 2021 - Abstract #AACRNCIEORTC2021AACR_NCI_EORTC_471;
- | IPN1087 / Fusion Pharma
Journal: Positron Emission Tomography Imaging of Neurotensin Receptor-Positive Tumors with Ga-Labeled Antagonists: The Chelate Makes the Difference Again. (Pubmed Central) - Aug 27, 2021
A small molecule NTS antagonist, named [Lu]Lu-IPN01087, is currently evaluated in phase I/II clinical trials for the targeted therapy of neurotensin receptor-positive cancers...Its rapid clearance from healthy tissues led to high tumor-to-organ ratios, resulting in highly contrasted PET images. These results were confirmed on subcutaneous xenografts of AsPC-1 tumor cells, a model of NTS-positive human pancreatic adenocarcinoma.
- |||| AAA614 / 3B Pharma, Novartis
New P1/2 trial: LuMIERE: A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2021
P1/2, N=170, Recruiting, Sponsor: Clovis Oncology, Inc.
- | Lu 177 zalsenertant tetraxetan (177Lu-IPN01087) / AstraZeneca
Enrollment change, Trial completion date, Trial termination: Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. (clinicaltrials.gov) - Jun 7, 2021
P1/2, N=14, Terminated, Sponsor: Ipsen
These results were confirmed on subcutaneous xenografts of AsPC-1 tumor cells, a model of NTS-positive human pancreatic adenocarcinoma. N=320 --> 14 | Trial completion date: Aug 2022 --> Apr 2021 | Recruiting --> Terminated; Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns
- || Lu 177 zalsenertant tetraxetan (177Lu-IPN01087) / AstraZeneca
Trial completion date: Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. (clinicaltrials.gov) - Feb 25, 2021
P1/2, N=320, Recruiting, Sponsor: Ipsen
N=320 --> 14 | Trial completion date: Aug 2022 --> Apr 2021 | Recruiting --> Terminated; Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns Trial completion date: Aug 2026 --> Aug 2022
- |||| 177 Lu PSMA-617 / RadioMedix, Excel Diagnostics, Novartis, FAP-2286 / Clovis, 3B Pharma
@clovisoncology $CLVS License 177Lu-FAP-2286 from 3B Pharmaceuticals a German company. @Endocyte $ECYT License 177Lu-PSMA-617 from German biotechnology company in 2017, for upfront payment of $12 million @Endocyte $ECYT was acquired for $2.1B by @Novartis in 2018. (Twitter) - Nov 30, 2020